Cognitive impairment in depression and cerebrovascular disease
https://doi.org/10.14412/2074-2711-2025-2-107-115
Abstract
The treatment of patients with cognitive impairment (CI) remains an urgent problem of modern neurology and psychiatrydue to the widespread prevalence of CI and the predicted increase in the number of patients in the future. Among the most common reasons for the development of cognitive deficits in young patients are depressive disorders, and in the elderly – vascular disease of the brain, Alzheimer's disease and their combination. We discuss pathophysiological features of CI in depression, and possible therapeutic options that allow to choose personalized therapy and improve the quality of life of patients.
About the Author
I. V. Reverchuk
Samarkand State Medical University;
Bioinstitute for Somatopsychiatric Healthcare
Russian Federation
Competing Interests:
Russian Federation
18, Amir Temur St., Samrkand 140100;
1, Mayskiy Lane, Kaliningrad 236038
Competing Interests:
The investigation has not been sponsored. There are no conflicts of interest. The author is solely responsible for submitting the final version of the manuscript for publication. The author has participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by the author.
References
1. Petersen RC. Clinical practice. Mild cognitive impairment. N Engl J Med. 2011 Jun 9;364(23):2227-34. doi: 10.1056/NEJMcp0910237
2. Pais R, Ruano L, Carvalho OP, Barros H. Global Cognitive Impairment Prevalence and Incidence in Community Dwelling Older AdultsA Systematic Review. Geriatrics (Basel). 2020 Oct 27;5(4):84. doi: 10.3390/geriatrics5040084
3. Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 Jan 16;90(3):126-35. doi: 10.1212/WNL.0000000000004826. Epub 2017 Dec 27.
4. Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014 Jul;44(10):2029-40. doi: 10.1017/S0033291713002535. Epub 2013 Oct 29.
5. Geda YE, Roberts RO, Mielke MM, et al. Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population-based study. Am J Psychiatry. 2014 May;171(5):572-81. doi: 10.1176/appi.ajp.2014.13060821
6. Perini G, Cotta Ramusino M, Sinforiani E, et al. Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatr Dis Treat. 2019 May 10;15:1249-58. doi: 10.2147/NDT.S199746
7. Schumacher A, Campisi SC, Khalfan AF, et al. Cognitive functioning in children and adolescents with depression: A systematic review and meta-analysis. Eur Neuropsychopharmacol. 2024 Feb;79:49-58. doi: 10.1016/j.euroneuro.2023.11.005. Epub 2023 Dec 20.
8. Badji A, Youwakim J, Cooper A, et al. Vascular cognitive impairment – Past, present, and future challenges. Ageing Res Rev. 2023 Sep;90:102042. doi: 10.1016/j.arr.2023.102042. Epub 2023 Aug 25.
9. Wu A, Zhang J. Neuroinflammation, memory, and depression: new approaches to hippocampal neurogenesis. J Neuroinflammation. 2023 Nov 27;20(1):283. doi: 10.1186/s12974-023-02964-x
10. Iadecola C. The pathobiology of vascular dementia. Neuron. 2013 Nov 20;80(4):844-66. doi: 10.1016/j.neuron.2013.10.008
11. Hachinski V, Einhäupl K, Ganten D, et al. Preventing dementia by preventing stroke: The Berlin Manifesto. Alzheimers Dement. 2019 Jul;15(7):961-84. doi: 10.1016/j.jalz.2019.06.001
12. Dean J, Keshavan M. The neurobiology of depression: An integrated view. Asian J Psychiatr. 2017 Jun;27:101-11. doi: 10.1016/j.ajp.2017.01.025. Epub 2017 Jan 29.
13. Semkovska M, Quinlivan L, O’Grady T, et al. Cognitive function following a major depressive episode: a systematic review and meta-analysis. Lancet Psychiatry. 2019 Oct;6(10):851-61. doi: 10.1016/S2215-0366(19)30291-3. Epub 2019 Aug 15.
14. Clinical guidelines. Cognitive disorders in elderly and senile individuals. Available at: https://cr.minzdrav.gov.ru/preview-cr/617_5 (accessed 21.03.2025) (In Russ.).
15. Preobrazhenskaya IS. Cognitive impairment and depression. Meditsinskiy sovet = Medical Council. 2023;(21):34-43. doi: 10.21518/ms2023-246 (In Russ.).
16. Gromova DO, Vakhnina NV. Acetylcholinergic Therapy in the Recovery Period of Ischemic Stroke. Effective Pharmacotherapy. 2019;15(34):26-34. doi: 10.33978/2307-3586-2019-15-34-26-34 (In Russ.).
17. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016 Jan;16(1):22-34. doi: 10.1038/nri.2015.5
18. Troubat R, Barone P, Leman S, et al. Neuroinflammation and depression: A review. Eur J Neurosci. 2021 Jan;53(1):151-71. doi: 10.1111/ejn.14720. Epub 2020 Mar 20.
19. Bhattacharya A, Derecki NC, Lovenberg TW, Drevets WC. Role of neuroimmunological factors in the pathophysiology of mood disorders. Psychopharmacology (Berl). 2016 May;233(9):1623-36. doi: 10.1007/s00213-016-4214-0. Epub 2016 Jan 23.
20. Pienaar L, Baijnath S, Millen AME. Unravelling the neuroinflammatory links in depression: the potential of a lipopolysaccharide preclinical model. Discover Med. 2024;1:1-18. doi: 10.1007/S44337-024-00114-7
21. Hassamal S. Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging antiinflammatories. Front Psychiatry. 2023 May 11;14:1130989. doi: 10.3389/fpsyt.2023.1130989
22. Ng A, Tam WW, Zhang MW, et al. IL-1β, IL-6, TNF-α and CRP in Elderly Patients with Depression or Alzheimer's disease: Systematic Review and Meta-Analysis. Sci Rep. 2018 Aug 13;8(1):12050. doi: 10.1038/s41598-018-30487-6
23. Elgellaie A, Thomas SJ, Kaelle J, et al. Pro-inflammatory cytokines IL-1β, IL-6 and TNF-α in major depressive disorder: Sex-specific associations with psychological symptoms. Eur J Neurosci. 2023 Jun;57(11):1913-28. doi: 10.1111/ejn.15992. Epub 2023 Apr 26.
24. Porter GA, O’Connor JC. Brain-derived neurotrophic factor and inflammation in depression: Pathogenic partners in crime? World J Psychiatry. 2022 Jan 19;12(1):77-97. doi: 10.5498/wjp.v12.i1.77
25. Yanushko MG, Shamanina MV. Neuroinflammation Factors and Cognitive Deficits in Recurrent Depression: The Search for Pathogenetic and Therapeutic Targets. Current Therapy of Mental Disorders. 2024;(4):22-8. doi: 10.21265/PSYPH.2024.61.34.003 (In Russ.).
26. Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience. 2013 Aug 29;246:199-229. doi: 10.1016/j.neuroscience.2013.04.060. Epub 2013 May 3.
27. Strawbridge R, Arnone D, Danese A, et al. Inflammation and clinical response to treatment in depression: A meta-analysis. Eur Neuropsychopharmacol. 2015 Oct;25(10):1532-43. doi: 10.1016/j.euroneuro.2015.06.007. Epub 2015 Jun 20.
28. Fard MT, Savage KM, Stough CK. Peripheral inflammation marker relationships to cognition in healthy older adults – A systematic review. Psychoneuroendocrinology. 2022 Oct;144:105870. doi: 10.1016/j.psyneuen.2022.105870. Epub 2022 Jul 13.
29. Vignjevic Petrinovic S, Milosevic MS, Markovic D, et al. Interplay between stress and cancer – A focus on inflammation. Front Physiol. 2023 Mar 20;14:1119095. doi: 10.3389/fphys.2023.1119095
30. Koo J, Marangell LB, Nakamura M, et al. Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol. 2017 Dec;31(12):1999-2009. doi: 10.1111/jdv.14460. Epub 2017 Aug 9.
31. Kopschina Feltes P, Doorduin J, Klein HC, et al. Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and nonresponders to standard antidepressant therapy. J Psychopharmacol. 2017 Sep;31(9):1149-65. doi: 10.1177/0269881117711708. Epub 2017 Jun 27.
32. Hollis F, Pope BS, Gorman-Sandler E, Wood SK. Neuroinflammation and Mitochondrial Dysfunction Link Social Stress to Depression. Curr Top Behav Neurosci. 2022;54:59-93. doi: 10.1007/7854_2021_300
33. Sharma C, Kim S, Nam Y, et al. Mitochondrial Dysfunction as a Driver of Cognitive Impairment in Alzheimer's Disease. Int J Mol Sci. 2021 May 3;22(9):4850. doi: 10.3390/ijms22094850
34. Rosnick CB, Rawson KS, Butters MA, Lenze EJ. Association of cortisol with neuropsychological assessment in older adults with generalized anxiety disorder. Aging Ment Health. 2013;17(4):432-40. doi: 10.1080/13607863.2012.761673. Epub 2013 Jan 22.
35. Hayley S, Hakim AM, Albert PR. Depression, dementia and immune dysregulation. Brain. 2021 Apr 12;144(3):746-60. doi: 10.1093/brain/awaa405
36. Caraci F, Copani A, Nicoletti F, Drago F. Depression and Alzheimer's disease: neurobiological links and common pharmacological targets. Eur J Pharmacol. 2010 Jan 10;626(1):64-71. doi: 10.1016/j.ejphar.2009.10.022. Epub 2009 Oct 18.
37. Rapp MA, Schnaider-Beeri M, Grossman HT, et al. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry. 2006 Feb;63(2):161-7. doi: 10.1001/archpsyc.63.2.161
38. McIntyre RS, Lee Y. Cognition in major depressive disorder: a 'Systemically Important Functional Index' (SIFI). Curr Opin Psychiatry. 2016 Jan;29(1):48-55. doi: 10.1097/YCO.0000000000000221
39. Baune BT, Renger L. Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression – a systematic review. Psychiatry Res. 2014 Sep 30;219(1):25-50. doi: 10.1016/j.psychres.2014.05.013. Epub 2014 May 14.
40. Knight EL, Engeland CG, Yocum AK, et al. Heightened inflammation in bipolar disorder occurs independent of symptom severity and is explained by body mass index. Brain Behav Immun Health. 2023 Mar 9;29:100613. doi: 10.1016/j.bbih.2023.100613
41. Rosenblat JD, McIntyre RS. Bipolar Disorder and Inflammation. Psychiatr Clin North Am. 2016 Mar;39(1):125-37. doi: 10.1016/j.psc.2015.09.006. Epub 2015 Dec 10.
42. Kennedy SH, Lam RW, McIntyre RS, et al; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry. 2016 Sep;61(9):540-60. doi: 10.1177/0706743716659417. Epub 2016 Aug 2. Erratum in: Can J Psychiatry. 2017 May;62(5):356. doi: 10.1177/0706743717708346
43. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Apr 7;391(10128):1357-66. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21.
44. Radulescu I, Dragoi AM, Trifu SC, Cristea MB. Neuroplasticity and depression: Rewiring the brain's networks through pharmacological therapy (Review). Exp Ther Med. 2021 Oct;22(4):1131. doi: 10.3892/etm.2021.10565. Epub 2021 Aug 5.
45. Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry. 2017 May;4(5):409-18. doi: 10.1016/S2215-0366(17)30015-9. Epub 2017 Jan 31.
46. Clinical guidelines. Depressive episode, Recurrent depressive disorder. Available at: https://cr.minzdrav.gov.ru/view-cr/301_3 (accessed 21.03.2025) (In Russ.).
47. Herrera-Guzman I, Gudayol-Ferre E, Herrera-Guzman D, et al. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J Psychiatr Res. 2009 Jun;43(9):855-63. doi: 10.1016/j.jpsychires.2008.10.015. Epub 2009 Jan 6.
48. Culang ME, Sneed JR, Keilp JG, et al. Change in cognitive functioning following acute antidepressant treatment in late-life depression. Am J Geriatr Psychiatry. 2009 Oct;17(10):881-8. doi: 10.1097/jgp.0b013e3181b4bf4a
49. Naji Esfahani H, Rafiee L, Haghjooy Javanmard S. Evaluation of the Effect of Antidepressant Drug, Fluvoxamine, on Cyclooxygenase-2 Protein Expression in Lipopolysaccharide-stimulated Macrophages. Adv Biomed Res. 2019 Jan 31;8:5. doi: 10.4103/abr.abr_141_18
50. Namiot ED, Smirnovova D, Sokolov AV, et al. Depression clinical trials worldwide: a systematic analysis of the ICTRP and comparison with ClinicalTrials.gov. Transl Psychiatry. 2024 Jul 31;14(1):315. doi: 10.1038/s41398-024-03031-6
51. Tynan RJ, Weidenhofer J, Hinwood M, et al. A comparative examination of the antiinflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun. 2012 Mar;26(3):469-79. doi: 10.1016/j.bbi.2011.12.011. Epub 2012 Jan 11.
52. Sigma receptors: new possibilities for the treatment of depression. Consilium Medicum. 2012;14(2):100-3 (In Russ.).
53. Bobrov AE, Krasnoslobodtseva LA, Mutnykh EM. Procognitive effects of fluvoxamine: Preliminary data. Zhurnal nevrologii i psihiatrii imeni SS Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(6):43-9. doi: 10.17116/JNEVRO20181186143 (In Russ.).
54. Mandelli L, Serretti A, Colombo C, et al. Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: an exploratory analysis. Psychiatry Clin Neurosci. 2006 Oct;60(5):598-604. doi: 10.1111/j.1440-1819.2006.01564.x
55. Nishimura T, Ishima T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS One. 2008 Jul 2;3(7):e2558. doi: 10.1371/journal.pone.0002558
56. Härtter S, Wang X, Weigmann H, et al. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol. 2001 Apr;21(2):167-74. doi: 10.1097/00004714-200104000-00008
57. Bobrov A, Krasnoslobodtseva L, Mutnykh E. Effects of Fluvoxamine on Cognitive Function in Outpatients with Depression in Remission: Results of an Open-Label Pilot Study. J Psychiatry. 2017;20:417. doi: 10.4172/2378-5756.1000417
58. Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol. 2010 Apr;25(3):193-200. doi: 10.1002/hup.1106
59. Rafiee L, Hajhashemi V, Javanmard SH. Fluvoxamine inhibits some inflammatory genes expression in LPS/stimulated human endothelial cells, U937 macrophages, and carrageenaninduced paw edema in rat. Iran J Basic Med Sci. 2016 Sep;19(9):977-84.
60. Hasebe S, Ago Y, Watabe Y, et al. Antianhedonic effect of selective serotonin reuptake inhibitors with affinity for sigma-1 receptors in picrotoxin-treated mice. Br J Pharmacol. 2017 Feb;174(4):314-27. doi: 10.1111/bph.13692. Epub 2017 Jan 26.
61. Li X, Yan D, Liao M, et al. Effect of fluvoxamine on plasma interleukin-6 in patients with major depressive disorder: a prospective follow-up study. Front Psychiatry. 2023 May 25;14:1163754. doi: 10.3389/fpsyt.2023.1163754
62. Villalain J. Location and interaction of idebenone and mitoquinone in a membrane similar to the inner mitochondrial membrane. Comparison with ubiquinone 10. Free Radic Biol Med. 2024 Sep;222:211-22. doi: 10.1016/j.freeradbiomed.2024.06.017. Epub 2024 Jun 20.
63. Boksha IS, Prokhorova TA, Savushkina OK, et al. Anomalies of Energy Metabolism in Schizophrenia and Possible PathogeneticTargeted Therapeutic Approaches. Neyrokhimiya. 2023;40(4):406-22. doi: 10.31857/S1027813323040088 (In Russ.).
64. General characteristics of the Noben®, capsules 30 mg, registration certificate number LP-No.(005244)-(RG-RU) dated 19.04.2024 (In Russ.).
65. Bergamasco B, Villardita C, Coppi R. Idebenone in the treatment of multi-infarct dementia: a randomised, double-blind, placebo controlled multicentre trial. Arch Gerontol Geriatr. 1992 Nov-Dec;15(3):271-8. doi: 10.1016/0167-4943(92)90062-9
66. Marigliano V, Abate G, Barbagallo-Sangiorgi G, et al. Randomized, double-blind, placebo controlled, multicentre study of idebenone in patients suffering from multi-infarct dementia. Arch Gerontol Geriatr. 1992 Nov-Dec;15(3):239-48. doi: 10.1016/0167-4943(92)90059-d
67. Lingetti M, Porfido FA, Ciarimboli M, et al. Evaluation of the clinical efficacy of idebenone in patients affected by chronic cerebrovascular disorders. Arch Gerontol Geriatr. 1992 Nov-Dec;15(3):225-37. doi: 10.1016/0167-4943(92)90058-c
68. Nappi G, Bono G, Merlo P, et al. Longterm idebenone treatment of vascular and degenerative brain disorders of the elderly. Arch Gerontol Geriatr. 1992 Nov-Dec;15(3):261-9. doi: 10.1016/0167-4943(92)90061-8
69. Muzychenko AP, Krasnoslobodtseva LA, Lubsanova SV. Clinical action of Noben in organic emotionally labile (asthenic) disorder. Nervous Diseases. 2008;(1):15-7 (In Russ.).
70. Gutzmann H, Kühl KP, Hadler D, Rapp MA. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallelgroup multicenter study. Pharmacopsychiatry. 2002 Jan;35(1):12-8. doi: 10.1055/s-2002-19833
71. Gutzmann H, Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. J Neural Transm Suppl. 1998;54:301-10. doi: 10.1007/978-3-7091-7508-8_30
72. Senin U, Parnetti L, Barbagallo-Sangiorgi G, et al. Idebenone in senile dementia of Alzheimer type: a multicentre study. Arch Gerontol Geriatr. 1992 NovDec;15(3):249-60. doi: 10.1016/0167-4943(92)90060-h
73. General characteristics of the medicinal product Phenibut, tablets 250 mg, registration certificate number LP-No. (003328)-(RG-RU) (In Russ.).
74. General characteristics of the medicinal product Prospecta, lozenges, 10,000 EMD, registration certificate number LP-No. (001963)-(RG-RU) (In Russ.).
75. General characteristics of the medicinal product Cytoflavin, enteric-coated tablets, registration certificate number LP-No. (000923)-(RG-RU) (In Russ.).
76. Instructions for medical use of the drug Enerion, film-coated tablets, 200 mg, registration certificate number P N011812/01 (In Russ.).
77. Instructions for medical use of the drug Noopept, tablets 10 mg, registration certificate number LS-001577 (In Russ.).
78. General characteristics of the drug Mexidol FORTE 250, film-coated tablets, 250 mg, registration certificate number LP-No. (000066)-(RG-RU) (In Russ.).
79. Instructions for medical use of the drug Phenotropil, tablets 50 mg, 100 mg, registration certificate number P N002784/01-080409 (In Russ.).
Review
For citations:
Reverchuk IV. Cognitive impairment in depression and cerebrovascular disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2025;17(2):107-115. (In Russ.) https://doi.org/10.14412/2074-2711-2025-2-107-115
Views:
158
Email this article 